FUJIFILM VisualSonics Can Now See a Tumor at 71 MHz. The Preclinical Imaging Arms Race Is Redefining What Drug Discovery Means.
June 2025: Breakthrough in Multi-Modal Resolution FUJIFILM VisualSonics commercially launched the Vevo F2 LAZR-X20, an integrated platform combining ultra-high frequency ultrasound (71 MHz) with photoacoustic imaging. This system enables researchers to visualize tumor microvessels and track immune cell infiltration in living subjects non-invasively and in real time.
Impact: This “category leap” resolves hemodynamic activity at sub-100-micron resolution, allowing the Global Preclinical Imaging Market to transition from terminal procedures to high-sensitivity, non-invasive longitudinal tracking.
2025-2026: The Rise of Multi-Parametric Hybrid Systems MILabs (Rigaku Corporation), Mediso, and Molecubes accelerated the deployment of compact PET/MRI and SPECT/CT hybrid systems. In early 2026, MILabs reported 14 new institutional deployments across Asia-Pacific for its U-CT/SPECT/PET systems, targeting high-throughput oncology and neuroscience programs.
Impact: The migration to multi-modality platforms provides simultaneous anatomical and functional data depth, significantly reducing the number of subjects required per study and cutting both costs and ethical exposure.
Ongoing 2026: Oncology as the Structural Growth Engine Oncology research continues to dominate market capacity, utilizing molecular imaging to monitor tumor heterogeneity and vascular recruitment. FUJIFILM VisualSonics reported over 8,000 peer-reviewed citations, cementing the platform’s role as the gold standard for translational research.
Impact: By detecting treatment responses at the microvascular level before anatomical changes appear, these systems provide a critical “early signal” that compresses drug-to-market timelines and reduces late-stage clinical failures.
Strategic Shift: Data-Driven Discovery Pipelines The industry has pivoted from hardware-centric specs to the speed of biological data conversion. Leading Contract Research Organizations (CROs) and pharma giants are investing in integrated multi-modality imaging platforms to automate quantification and enhance drug safety assessments.
Impact: This structural shift underpins the market’s 8.36% CAGR, as the ability to non-invasively quantify drug response fundamentally changes the economics of the global drug discovery and development pipeline.
Explore the Full Market Intelligence